Investigating the role of anti-angiogenic FKBPL in trophoblast differentiation (144012)
Ananya Raman
1
,
Taj Graham
1
,
Maia McCalmont Parkinson
1
,
Claire Richards
1
2
,
Louise Cole
3
,
Lana McClements
1
2
- School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW, Australia
- Institute for Biomedical Materials and Devices, Faculty of Science, University of Technology Sydney, Sydney, NSW, Australia
- Australian Institute for Microbiology and Infection (AIMI), Faculty of Science, University of Technology Sydney, Sydney, NSW, Australia
Publish consent withheld
- Todd N, McNally R, et al. Role of A Novel Angiogenesis FKBPL-CD44 Pathway in Preeclampsia Risk Stratification and Mesenchymal Stem Cell Treatment. Journal of Clinical Endocrinology and Metabolism 2021;106(1): 26–41.
- McClements L, Yakkundi A, et al. Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway. Clinical Cancer Research 2013;19(14):3881-3893.